Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic

M. Kojanova, P. Cetkovska, D. Strosova, J. Fialova, P. Arenberger, T. Dolezal, S. Gkalpakiotis, BIOREP Study Group

. 2021 ; 11 (2) : 543-553. [pub] 20210305

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21010281

INTRODUCTION: The study aimed to evaluate the real-world effectiveness of adalimumab as well as investigate the persistence of treatment and identify factors, which may affect it. METHODS: More than 1150 patients (4363.1 patient-years) with psoriasis who had been treated with adalimumab since the start of the BIOREP registry in the Czech Republic were included in this analysis. Treatment effectiveness was defined as improvement in Psoriasis Area and Severity Index (PASI). The analysis was performed during the years 2005 and 2018. Patients were on on-label dose. RESULTS: After 12 and 96 months of therapy, 84% and 88% of patients had a 75% reduction in PASI score from baseline, respectively. Drug survival was analyzed according to the number of previous biological therapies, and results showed 75% and 58.1% survival rate for biologically naïve patients in the 20th and 80th month of treatment, respectively. The negative predictors of adalimumab survival were the female gender, obesity, baseline PASI score and the number of previous biological therapies. CONCLUSIONS: Baseline factors including PASI, number of previous biological therapies, and sex were associated with shorter adalimumab survival. This long-term study shows that adalimumab is effective and has high treatment persistence.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010281
003      
CZ-PrNML
005      
20210610095947.0
007      
ta
008      
210413s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13555-021-00499-8 $2 doi
035    __
$a (PubMed)33666877
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kojanova, Martina $u Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. kojanova.martina@vfn.cz
245    10
$a Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic / $c M. Kojanova, P. Cetkovska, D. Strosova, J. Fialova, P. Arenberger, T. Dolezal, S. Gkalpakiotis, BIOREP Study Group
520    9_
$a INTRODUCTION: The study aimed to evaluate the real-world effectiveness of adalimumab as well as investigate the persistence of treatment and identify factors, which may affect it. METHODS: More than 1150 patients (4363.1 patient-years) with psoriasis who had been treated with adalimumab since the start of the BIOREP registry in the Czech Republic were included in this analysis. Treatment effectiveness was defined as improvement in Psoriasis Area and Severity Index (PASI). The analysis was performed during the years 2005 and 2018. Patients were on on-label dose. RESULTS: After 12 and 96 months of therapy, 84% and 88% of patients had a 75% reduction in PASI score from baseline, respectively. Drug survival was analyzed according to the number of previous biological therapies, and results showed 75% and 58.1% survival rate for biologically naïve patients in the 20th and 80th month of treatment, respectively. The negative predictors of adalimumab survival were the female gender, obesity, baseline PASI score and the number of previous biological therapies. CONCLUSIONS: Baseline factors including PASI, number of previous biological therapies, and sex were associated with shorter adalimumab survival. This long-term study shows that adalimumab is effective and has high treatment persistence.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cetkovska, Petra $u Department of Dermatovenereology, Faculty of Medicine and University Hospital, Charles University, Pilsen, Czech Republic
700    1_
$a Strosova, Daniela $u Value Outcomes, Prague, Czech Republic
700    1_
$a Fialova, Jorga $u Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Arenberger, Petr $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic
700    1_
$a Dolezal, Tomas $u Value Outcomes, Prague, Czech Republic
700    1_
$a Gkalpakiotis, Spyridon $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic
710    2_
$a BIOREP Study Group
773    0_
$w MED00207103 $t Dermatology and therapy $x 2193-8210 $g Roč. 11, č. 2 (2021), s. 543-553
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33666877 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210610095947 $b ABA008
999    __
$a ind $b bmc $g 1649758 $s 1130657
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 2 $d 543-553 $e 20210305 $i 2193-8210 $m Dermatology and therapy $n Dermatol Ther (Heidelb) $x MED00207103
LZP    __
$a Pubmed-20210413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace